Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting langerhans cell migration

Abstract

The invention concerns a pharmaceutical or cosmetic composition, characterized in that it comprises at least a compound for inhibiting Langerhans' cell migration, said active compound being selected in the group consisting of protein kinase C (PKC) inhibiting compounds, matrix metalloprotease (MMP) inhibiting compounds, and combinations thereof, and at least a pharmaceutically or cosmetically acceptable carrier. Said composition enables to inhibit considerably Langerhans' cell migration induced by the presence of an allergenic agent.

1 . A method for the treatment of disorders of the skin or mucous membranes linked to Langerhans' cells migration comprising the administration of an effective amount of a composition comprising at least one retinoid to a person in need thereof. 
     
     
         2 . The method of  claim 1 , wherein said disorder is selected from the group consisting of allergic reactions, atopic eczema, contact eczema, skin sensibility, skin reactivity, inflammatory dermatosis, irritant dermatitis, transplant rejection, autoimmune diseases, inflammatory diseases, psoriasis and photo immuno suppression. 
     
     
         3 . The method of  claim 1 , wherein said retinoid is selected from the group consisting of nonaromatic retinoids, vitamin A, monoaromatic retinoids and polyaromatic retinoids. 
     
     
         4 . The method of  claim 3 , wherein said nonaromatic retinoid is selected from the group consisting of retinaldehyde, tretinoin and 9-cis-retinoic acid. 
     
     
         5 . The method of  claim 3 , wherein said monoaromatic retinoid is selected from the group consisting of etretinade, all-trans-acitretin and motrerinide. 
     
     
         6 . The method of  claim 3 , wherein said polyaromatic retinoid is selected from the group consisting of adapalene, tazarotene, tamibarotere and arotinoid methyl sulfone. 
     
     
         7 . The method of  claim 1 , wherein the composition further comprises a PKC-inhibitor selected from the group consisting of peptide extracts of lupin, sphingolipids and ceramids. 
     
     
         8 . The method of  claim 7 , wherein the sphingolipid is selected from the group consisting of sphingosine, phytosphingosine and isomers thereof. 
     
     
         9 . The method of  claim 7 , wherein the peptide extract of lupin is LU105. 
     
     
         10 . The method of  claim 1 , wherein the retinoid concentration in the composition is between approximatively 0.001 and approximatively 10% by weight, relative to the total weight of the composition. 
     
     
         11 . A method for the treatment of disorders of the skin or mucous membranes linked to Langerhans' cells migration comprising the administration of an effective amount of a composition comprising at least one retinoid selected from the group consisting of vitamin A and 9-cis-retinoic acid to a person in need thereof.